Skip to Main Content

2,867

Views

13

CrossRef citations to date

0

Altmetric

Original Articles: Clinical

Efficacy and safety of frontline rituximab, cyclophosphamide, doxorubicin and prednisone plus bortezomib (VR-CAP) or vincristine (R-CHOP) in a subset of newly diagnosed mantle cell lymphoma patients medically eligible for transplantation in the randomized, phase 3 LYM-3002 study

Johannes DrachMedical University of Vienna, Vienna General Hospital, Vienna, Austria; Correspondence[email protected]
View further author information

,

Huiqiang HuangSun Yat-sen University Cancer Center, Guangzhou, Guangdong, China; View further author information

,

Olga SamoilovaNizhniy Novgorod Region Clinical Hospital, Nizhniy Novgorod, Russian Federation; View further author information

,

Andrew BelchUniversity of Alberta, Cross Cancer Institute, Edmonton, AB, Canada; View further author information

,

Charles FarberCarol G. Simon Cancer Center, Morristown, NJ, USA; View further author information

,

André BoslyCHU Dinant-Godinne UCL Namur, Yvoir, Belgium; View further author information

,

Jan NovakCharles University in Prague, Prague, Czech Republic; View further author information

,

Jan ZauchaGdynia Oncology Center & Medical University of Gdansk, Gdynia, Poland; View further author information

,

Angela DascalescuInstitutul Regional de Oncologie Iasi, Judetul, lasi, Romania; View further author information

,

Udomsak BunworasateKing Chulalongkorn Memorial Hospital, Chulalongkorn University, Bangkok, Thailand; View further author information

,

Zvenyslava MasliakInstitute of Blood Pathology and Transfusion Medicine of National Academy of Medical Sciences of Ukraine, Lviv, Ukraine; View further author information

,

Kateryna VilchevskayaInstitute of Urgent and Recovery Surgery n.a V.K. Gusaka of AMS of Ukraine, Donetsk, Ukraine; View further author information

,

Tadeusz RobakMedical University of Lodz, Copernicus Memorial Hospital, Lodz, Poland; View further author information

,

Lixia PeiJanssen Research & Development, LLC, Raritan, NJ, USA; View further author information

,

Brendan RooneyJanssen Research & Development, High Wycombe, United Kingdom; View further author information

,

Helgi van de VeldeMillennium Pharmaceuticals, Inc, Boston, MA, USA; View further author information

&

Franco CavalliOncology Institute of Southern Switzerland Ospedale San Giovanni, Bellinzona, SwitzerlandView further author information